ARS Pharmaceuticals
SPRY
SPRY
115 hedge funds and large institutions have $533M invested in ARS Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 46 increasing their positions, 24 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
2% more funds holding
Funds holding: 113 → 115 (+2)
13% less capital invested
Capital invested by funds: $612M → $533M (-$79M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Holders
115
Holding in Top 10
2
Calls
$19.2M
Puts
$821K
Top Buyers
| 1 | +$12.1M | |
| 2 | +$3.1M | |
| 3 | +$2.72M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.14M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.06M |
Top Sellers
| 1 | -$2.71M | |
| 2 | -$1.03M | |
| 3 | -$1.02M | |
| 4 |
Capstone Investment Advisors
New York
|
-$739K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$705K |